Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2 multi-center, open-label study to evaluate the efficacy and safety of patient-specific immunotherapy, recombinant idiotype conjugated to KLH (Id-KLH) and administered with GM-CSF, in patients with follicular non-Hodgkin's lymphoma following primary treatment with rituximab and chemotherapy (R-Chemo)

Next Previous
X
Search
Trial Profile

Phase 2 multi-center, open-label study to evaluate the efficacy and safety of patient-specific immunotherapy, recombinant idiotype conjugated to KLH (Id-KLH) and administered with GM-CSF, in patients with follicular non-Hodgkin's lymphoma following primary treatment with rituximab and chemotherapy (R-Chemo)

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 10 Nov 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GTOP 99 (Primary) ; Sargramostim (Primary)
  • Indications Follicular lymphoma
  • Focus Therapeutic Use
  • Sponsors Genitope Corporation

    • Most Recent Events

    • 17 Mar 2008 Status changed from recruiting to discontinued as reported by ClinicalTrial.gov
    • 30 May 2007 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top